Clinical Trials Logo

Fecal Microbiota clinical trials

View clinical trials related to Fecal Microbiota.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06423508 Not yet recruiting - Gut Microbiome Clinical Trials

PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals

PROTEGI
Start date: June 3, 2024
Phase:
Study type: Observational

The study aims to assess the effectiveness of various commercial and non-hazardous buffers for the storage of human gut fecal samples over time. This evaluation will be conducted by comparing the performance of these buffers against directly frozen samples using metaproteomic analysis. The study is motivated by the need for standardized protocols for sample preservation in metaproteomic research, particularly focusing on protein preservation in fecal samples. By investigating proteomic, taxonomic, and functional identifications, the research seeks to provide insights into the reliability of these buffers as storage solutions. Additionally, the study plans to explore inter- and intra-individual variabilities at the proteome level by periodically collecting fecal samples from volunteers, complementing existing knowledge in metaproteomics. Overall, the study addresses a critical gap in the field and has the potential to enhance reproducibility and comparability across metaproteomic studies

NCT ID: NCT04198402 Not yet recruiting - Fecal Microbiota Clinical Trials

Microbiotic Analysis in Digestive Endocrine Tumors

MicroTEND
Start date: January 2020
Phase:
Study type: Observational

Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.